MCID: ACT200
MIFTS: 56

Acute Monoblastic Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Acute Monoblastic Leukemia

MalaCards integrated aliases for Acute Monoblastic Leukemia:

Name: Acute Monoblastic Leukemia 53 59 6 72
Acute Monocytic Leukemia 53 59 72
Aml M5 53 59
M5b Acute Differentiated Monocytic Leukemia 72
Acute Monocytic/monoblastic Leukemia 72
Acute Myeloblastic Leukemia Type 5 53
Aml-M5 53

Characteristics:

Orphanet epidemiological data:

59
acute monoblastic leukemia
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

Classifications:



External Ids:

ICD10 33 C93.0
MESH via Orphanet 45 D007948
ICD10 via Orphanet 34 C92.7
UMLS via Orphanet 73 C0023465 C0457334 C1318544
Orphanet 59 ORPHA514
UMLS 72 C0023465 C0457334 C1318544 more

Summaries for Acute Monoblastic Leukemia

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 514DefinitionAcute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).Visit the Orphanet disease page for more resources.

MalaCards based summary : Acute Monoblastic Leukemia, also known as acute monocytic leukemia, is related to monocytic leukemia and thrombocytosis. An important gene associated with Acute Monoblastic Leukemia is LPP (LIM Domain Containing Preferred Translocation Partner In Lipoma), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are acute monocytic leukemia and fatigue

Related Diseases for Acute Monoblastic Leukemia

Diseases related to Acute Monoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 monocytic leukemia 30.5 KMT2A IL6 CXCL8 CSF2
2 thrombocytosis 30.2 IL6 EPO CSF2
3 bacterial infectious disease 30.1 IL6 CXCL8 CSF2
4 myeloma, multiple 29.5 IL6 EPO CXCL8 CSF2 CD44
5 juvenile myelomonocytic leukemia 29.4 SOS1 NF1 CSF2
6 adult acute monocytic leukemia 12.9
7 leukemia, acute monocytic 11.9
8 leukemia 10.9
9 intracranial berry aneurysm 10.7 PKD1 NF1
10 leukemia, acute myeloid 10.7
11 polycystic kidney disease, infantile severe, with tuberous sclerosis 10.7 TSC2 PKD1
12 acute leukemia 10.6
13 myeloid leukemia 10.6
14 myeloid sarcoma 10.5
15 sarcoma 10.5
16 spindle cell sarcoma 10.5
17 vibrio vulnificus infection 10.4 IL6 EPO
18 disseminated intravascular coagulation 10.4
19 chromosomal triplication 10.4
20 recurrent corneal erosion 10.4 IL6 CXCL8
21 engraftment syndrome 10.4 CXCL8 CSF2
22 autosomal genetic disease 10.4 TSC2 PKD1 NF1
23 bagassosis 10.4 IL6 CXCL8
24 lymphocytic leukemia 10.4
25 streptococcal toxic-shock syndrome 10.4 IL6 CXCL8
26 pancytopenia 10.4
27 47,xyy 10.4
28 acute transverse myelitis 10.3 IL6 CXCL8
29 felty syndrome 10.3 CXCL8 CSF2
30 neuroblastoma 1 10.3
31 myelodysplastic syndrome 10.3
32 denture stomatitis 10.3 IL6 CXCL8
33 leukemia, acute lymphoblastic 10.2
34 histiocytosis 10.2
35 hematopoietic stem cell transplantation 10.2
36 tuberous sclerosis 10.2 TSC2 STK11 PKD1 NF1
37 capillary leak syndrome 10.2 IL6 CXCL8 CSF2
38 meconium aspiration syndrome 10.2 IL6 CXCL8 CSF2
39 end stage renal failure 10.2 PKD1 IL6 EPO
40 mastitis 10.2 IL6 CXCL8 CSF2
41 b-cell growth factor 10.2 IL7 IL6
42 intestinal disease 10.2 STK11 IL6 CXCL8
43 bronchial disease 10.2 IL6 CXCL8 CSF2
44 urinary system disease 10.2 PKD1 IL6 EPO
45 chronic myelomonocytic leukemia 10.2
46 funisitis 10.2 IL6 CXCL8
47 osteogenic sarcoma 10.2
48 aspergillosis 10.2
49 respiratory failure 10.2
50 hemopericardium 10.2

Graphical network of the top 20 diseases related to Acute Monoblastic Leukemia:



Diseases related to Acute Monoblastic Leukemia

Symptoms & Phenotypes for Acute Monoblastic Leukemia

Human phenotypes related to Acute Monoblastic Leukemia:

59 32 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 acute monocytic leukemia 59 32 obligate (100%) Obligate (100%) HP:0004845
2 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
3 exertional dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002875
4 lymphocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0100827
5 bone marrow hypercellularity 59 32 frequent (33%) Frequent (79-30%) HP:0031020
6 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
7 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
8 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
9 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
10 increased lactate dehydrogenase activity 59 32 occasional (7.5%) Occasional (29-5%) HP:0025435
11 hypochromic anemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001931
12 periorbital edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0100539
13 ankle swelling 59 32 occasional (7.5%) Occasional (29-5%) HP:0001785
14 progressive hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0001730
15 oliguria 59 32 occasional (7.5%) Occasional (29-5%) HP:0100520
16 central hypothyroidism 59 32 occasional (7.5%) Occasional (29-5%) HP:0011787
17 cervical lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0025289
18 anemia 59 Frequent (79-30%)
19 leukocytosis 59 Frequent (79-30%)
20 abnormality of multiple cell lineages in the bone marrow 59 Occasional (29-5%)

MGI Mouse Phenotypes related to Acute Monoblastic Leukemia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 CD44 CSF2 EPO GPHN IL6 KMT2A
2 hematopoietic system MP:0005397 10.28 CD44 CSF2 EPO IL6 IL7 KMT2A
3 cardiovascular system MP:0005385 10.27 CD44 CSF2 EPO IL6 KMT2A NF1
4 homeostasis/metabolism MP:0005376 10.26 CD44 CSF2 EPO IL6 KMT2A LPP
5 mortality/aging MP:0010768 10.23 CD44 CSF2 EPO GPHN IL6 KMT2A
6 immune system MP:0005387 10.21 CD44 CSF2 EPO IL6 IL7 KMT2A
7 endocrine/exocrine gland MP:0005379 10.2 CD44 CSF2 IL6 IL7 NF1 PKD1
8 integument MP:0010771 10.19 CD44 CSF2 EPO IL6 KMT2A NF1
9 embryo MP:0005380 10.16 CSF2 EPO KMT2A NF1 PKD1 SOS1
10 liver/biliary system MP:0005370 10.08 CD44 EPO IL6 KMT2A NF1 PKD1
11 nervous system MP:0003631 10.07 CD44 CSF2 GPHN IL6 KMT2A NF1
12 muscle MP:0005369 10.03 CD44 EPO IL6 KMT2A NF1 PKD1
13 neoplasm MP:0002006 10.01 CD44 CSF2 IL6 KMT2A NF1 PKD1
14 normal MP:0002873 9.92 CD44 EPO GPHN KMT2A NF1 PKD1
15 renal/urinary system MP:0005367 9.86 CD44 CSF2 IL6 KMT2A NF1 PKD1
16 reproductive system MP:0005389 9.76 CD44 CSF2 IL6 KMT2A LPP PKD1
17 respiratory system MP:0005388 9.56 CD44 CSF2 EPO GPHN IL6 NF1
18 skeleton MP:0005390 9.23 CD44 CSF2 EPO IL6 KMT2A NF1

Drugs & Therapeutics for Acute Monoblastic Leukemia

Drugs for Acute Monoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Lenograstim Approved, Investigational Phase 3 135968-09-1
7
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
10
leucovorin Approved Phase 3 58-05-9 143 6006
11
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
12
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
13
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
14
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
15
Melphalan Approved Phase 3 148-82-3 460612 4053
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
Carmustine Approved, Investigational Phase 3 154-93-8 2578
18
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
19
Hydroxyurea Approved Phase 3 127-07-1 3657
20
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
23
Daunorubicin Approved Phase 3 20830-81-3 30323
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
27
Histamine Approved, Investigational Phase 3 51-45-6 774
28
Cyproheptadine Approved Phase 3 129-03-3 2913
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31 Lintuzumab Investigational Phase 3 166089-32-3
32
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
33 Staurosporine Experimental Phase 3 62996-74-1
34 Vaccines Phase 3
35 Antibodies Phase 3
36 Antibodies, Monoclonal Phase 3
37 Immunoglobulins Phase 3
38 Gemtuzumab Phase 3
39 Antineoplastic Agents, Immunological Phase 3
40 Antirheumatic Agents Phase 3
41 Antineoplastic Agents, Phytogenic Phase 3
42 Adjuvants, Immunologic Phase 3
43 Etoposide phosphate Phase 3
44 Analgesics Phase 3
45 Protective Agents Phase 3
46 Radiation-Protective Agents Phase 3
47 Nucleic Acid Synthesis Inhibitors Phase 3
48 Folic Acid Antagonists Phase 3
49 Folate Phase 3
50 Vitamin B9 Phase 3

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
4 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
5 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
6 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
7 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
8 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
9 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
10 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
11 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
12 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
13 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
14 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
15 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
16 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
17 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
19 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
20 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
22 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
23 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
24 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
25 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
26 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
27 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
28 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
29 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
30 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
31 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
32 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
33 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
34 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene
35 Pilot Study of Sodium Phenylbutyrate Plus Azacytidine Completed NCT00006019 Phase 2 azacitidine;sodium phenylbutyrate
36 A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60 Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
37 A Phase II Study of Allografting to Establish Mixed or Full Donor Chimerism as Consolidative Immunotherapy for Older Patients With AML in Complete Remission Using Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00005801 Phase 2
38 Phase II Study of High-Dose Busulfan and Cyclophosphamide Followed by Allogeneic Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia Completed NCT00004896 Phase 2 busulfan;cyclophosphamide
39 A Phase II Study of Gemtuzumab Ozogamicin (Mylotarg) and Standard Dose ARA-C for Patients With Relapsed Acute Myeloid Leukemia (AML) Completed NCT00049179 Phase 2 cytarabine;gemtuzumab ozogamicin
40 Idarubicin and Cladribine in Recurrent and Refractory Acute Myeloid Leukemia: A POG Phase II Study Completed NCT00003178 Phase 2 cladribine;idarubicin
41 Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
42 A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
43 ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA Completed NCT00002547 Phase 2 busulfan;cyclophosphamide;cyclosporine;cytarabine;methotrexate
44 An Open Label Phase II Trial of Clofarabine and Temsirolimus in Older Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Completed NCT00775593 Phase 2 clofarabine;temsirolimus
45 Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study Completed NCT00006122 Phase 2 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
46 A Phase II Randomized Trial of Immunologic and Chemotherapeutic Agents for Treatment of Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed NCT00005962 Phase 2 cyclophosphamide;cytarabine;gemtuzumab ozogamicin;liposomal daunorubicin citrate;topotecan hydrochloride
47 A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide (DATE) for De Novo AML: In the Treatment of Young Patients Ages 16-59 Completed NCT00005793 Phase 1, Phase 2 Cytarabine;Daunorubicin;Etoposide;Topotecan
48 A Phase II Study of Daunomycin and ARA-C Given by Continuous IV Infusion With PSC-833 for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older Completed NCT00004217 Phase 2 cytarabine;daunorubicin hydrochloride;valspodar
49 Clinical Protocol for a Phase II Study of Leridistim (SC-70935) in Adult Patients (Age>55) With Acute Myeloid Leukemia (AML) Receiving Chemotherapy With the Cytarabine and Daunorubicin "7+3" Regimen Completed NCT00004215 Phase 2 cytarabine;daunorubicin hydrochloride
50 A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen Completed NCT00070135 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus

Search NIH Clinical Center for Acute Monoblastic Leukemia

Genetic Tests for Acute Monoblastic Leukemia

Anatomical Context for Acute Monoblastic Leukemia

MalaCards organs/tissues related to Acute Monoblastic Leukemia:

41
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Skin, Endothelial

Publications for Acute Monoblastic Leukemia

Articles related to Acute Monoblastic Leukemia:

(show top 50) (show all 1178)
# Title Authors PMID Year
1
D-4F, an apolipoprotein A-I mimetic, suppresses IL-4 induced macrophage alternative activation and pro-fibrotic TGF-β1 expression. 38
31335245 2019
2
MicroRNA‑217 is involved in the progression of atherosclerosis through regulating inflammatory responses by targeting sirtuin 1. 38
31432137 2019
3
[The value of detecting MLL gene rearrangement in children with acute monocytic leukemia]. 38
31400126 2019
4
Cytogenetics and associated mutation profile in patients with acute monocytic leukemia. 38
31099482 2019
5
Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro. 38
31115604 2019
6
Characteristic genes in THP‑1 derived macrophages infected with Mycobacterium tuberculosis H37Rv strain identified by integrating bioinformatics methods. 38
31364746 2019
7
Molecular hydrogen suppresses free radical-induced cell death by mitigating fatty acid peroxidation and mitochondrial dysfunction. 38
31295412 2019
8
Making it stick: A CURE designed to introduce students to the scientific process and the host response to foreign materials. 38
31002463 2019
9
Red blood cells participate in reverse cholesterol transport by mediating cholesterol efflux of high-density lipoprotein and apolipoprotein A-I from THP-1 macrophages. 38
31188743 2019
10
[Cloning of New Antigen Gene MLAA-34 Promoter and Identification of Core Region in Acute Monocytic Leukemia]. 38
31204911 2019
11
Pd(II) complexes with N-heteroaromatic hydrazone ligands: Anticancer activity, in silico and experimental target identification. 38
31299379 2019
12
[Characterizing the molecular cytogenetics in acute monocytic leukemia]. 38
31055804 2019
13
Ets1 Plays a Critical Role in MLL/EB1-Mediated Leukemic Transformation in a Mouse Bone Marrow Transplantation Model. 38
30974389 2019
14
Extracellular Vesicles from Interferon-γ-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats. 38
30870158 2019
15
Eutopic endometrium from patients with endometriosis modulates the expression of CD36 and SIRP-α in peritoneal macrophages. 38
30843336 2019
16
Albiflorin inhibits the formation of THP-1-derived foam cells through the LOX-1/NF-κB pathway. 38
30371044 2019
17
HMGB1 from Lampetra japonica promotes inflammatory activation in supraneural body cells. 38
30423344 2019
18
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. 38
30885156 2019
19
Non-acute promyelocytic leukemia variant, acute myeloid leukemia with translocation (11;17). 38
30899494 2019
20
Tetrasomy 8 Associated with a Poor Prognosis in Acute Monoblastic Leukemia: A Case Report. 38
31016095 2019
21
Oxidized LDL, homocysteine, homocysteine thiolactone and advanced glycation end products act as pro-oxidant metabolites inducing cytokine release, macrophage infiltration and pro-angiogenic effect in ARPE-19 cells. 38
31086404 2019
22
Downregulation of LPXN expression by siRNA decreases the malignant proliferation and transmembrane invasion of SHI-1 cells. 38
30655748 2019
23
Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia. 38
30747080 2019
24
Tanshinone IIA induces apoptosis and autophagy in acute monocytic leukemia via downregulation of PI3K/Akt pathway. 38
31217869 2019
25
Spontaneous remission of acute monocytic leukemia with trisomy 8 and trisomy 18. 38
31257350 2019
26
Differential Immunomodulatory Effect of Graphene Oxide and Vanillin-Functionalized Graphene Oxide Nanoparticles in Human Acute Monocytic Leukemia Cell Line (THP-1). 38
30634552 2019
27
Facial paralysis as a presenting symptom of infant leukemia: A case report and literature review. 38
30572489 2018
28
Advanced microRNA-based cancer diagnostics using amplified time-gated FRET. 38
30542553 2018
29
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report. 38
30431598 2018
30
Regulatory roles of miR-155 and let-7b on the expression of inflammation-related genes in THP-1 cells: effects of fatty acids. 38
29790117 2018
31
Induction of apoptosis in human acute monocytic leukemia (THP-1) cells with NaF and the related mechanisms. 38
30610810 2018
32
Atypical Acute Monocytic Leukemia: a Lymphoma Presentation and Association with Complex Karyotype. 38
30610055 2018
33
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice. 38
30354818 2018
34
Imidazo[1,2-b]pyrazole-7-carboxamides Induce Apoptosis in Human Leukemia Cells at Nanomolar Concentrations. 38
30388846 2018
35
Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A. 38
30631409 2018
36
Overexpression of miR‑21 is involved in acute monocytic leukemia‑associated angiogenesis by targeting IL‑12. 38
30106099 2018
37
[Expression of triggering receptors expressed by myeloid cells-1 in macrophages stimulated by Porphyromonas gingivalis-lipopolysaccharide]. 38
30465338 2018
38
Clonal neutrophil infiltrates in concurrent Sweet's syndrome and acute myeloid leukemia: A case report and literature review. 38
30005849 2018
39
Colon cancer-derived conditioned medium induces differentiation of THP-1 monocytes into a mixed population of M1/M2 cells. 38
30183516 2018
40
Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. 38
29417354 2018
41
Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins αMβ2 and αVβ3. 38
29852400 2018
42
High glucose induces dysfunction of human umbilical vein endothelial cells by upregulating miR-137 in gestational diabetes mellitus. 38
29505767 2018
43
Sera from Septic Patients Contain the Inhibiting Activity of the Extracellular ATP-Dependent Inflammasome Pathway. 38
30033950 2018
44
Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage. 38
29991810 2018
45
Acute myeloid leukemia with severe coagulation disorder and concomitant central nervous system bleeding - a clinical diagnostic case report. 38
30050398 2018
46
Histiocytic sarcoma of the neck: A case report. 38
29977539 2018
47
Akt, mTOR and NF-κB pathway activation in Treponema pallidum stimulates M1 macrophages. 38
29656208 2018
48
A simplified sheathless cell separation approach using combined gravitational-sedimentation-based prefocusing and dielectrophoretic separation. 38
29725680 2018
49
Nickel(II) bis(isatin thiosemicarbazone) complexes induced apoptosis through mitochondrial signaling pathway and G0/G1 cell cycle arrest in IM-9 cells. 38
29510336 2018
50
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. 38
29843647 2018

Variations for Acute Monoblastic Leukemia

ClinVar genetic disease variations for Acute Monoblastic Leukemia:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11): c.970C> G (p.Pro324Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs549474196 19:1223033-1223033 19:1223034-1223034
2 NF1 NM_000267.3(NF1): c.1588G> A (p.Val530Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs145191978 17:29546083-29546083 17:31219065-31219065
3 NF1 NM_000267.3(NF1): c.2747A> G (p.Asn916Ser) single nucleotide variant Uncertain significance rs765043916 17:29556380-29556380 17:31229362-31229362
4 TSC2 NM_000548.5(TSC2): c.5336A> G (p.Gln1779Arg) single nucleotide variant Benign/Likely benign rs748947919 16:2138523-2138523 16:2088522-2088522
5 SOS1 NM_005633.3(SOS1): c.2371C> A (p.Leu791Ile) single nucleotide variant Benign rs142004123 2:39239286-39239286 2:39012145-39012145

Expression for Acute Monoblastic Leukemia

Search GEO for disease gene expression data for Acute Monoblastic Leukemia.

Pathways for Acute Monoblastic Leukemia

Pathways related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 SOS1 NF1 IL7 IL6 CXCL8 CSF2
2
Show member pathways
12.77 TSC2 STK11 SOS1 IL7 IL6 EPO
3 12.69 SOS1 IL7 IL6 EPO CXCL8
4
Show member pathways
12.13 SOS1 IL7 IL6 EPO CSF2
5 12.08 KMT2A IL6 CXCL8 CSF2
6 11.83 TSC2 SOS1 NF1
7 11.79 IL6 CXCL8 CSF2
8
Show member pathways
11.74 IL6 CXCL8 CSF2
9 11.74 IL6 CXCL8 CSF2
10 11.67 IL6 CXCL8 CSF2
11 11.67 IL6 CXCL8 CSF2
12 11.58 KMT2A IL6 CXCL8 CD44
13
Show member pathways
11.52 IL6 CXCL8 CSF2
14 11.51 IL6 CXCL8 CSF2
15 11.44 NF1 IL6 CXCL8
16 11.42 IL7 IL6 EPO CSF2 CD44
17 11.34 IL6 CXCL8 CSF2
18 11.29 IL6 EPO CSF2
19 11.16 SOS1 IL6 CXCL8 CD44
20 11.1 NF1 CXCL8 CSF2
21 11.03 IL7 IL6 CXCL8 CSF2
22 11.01 IL7 IL6 EPO CSF2 CD44
23 10.96 IL7 IL6 CSF2
24 10.9 IL6 CXCL8

GO Terms for Acute Monoblastic Leukemia

Biological processes related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of chemokine production GO:0032722 9.37 IL7 IL6
2 negative regulation of cell proliferation GO:0008285 9.35 TSC2 STK11 NF1 IL6 CXCL8
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.33 IL6 EPO CSF2
4 anoikis GO:0043276 9.32 TSC2 STK11
5 response to fluid shear stress GO:0034405 9.26 PKD1 CSF2
6 cytokine-mediated signaling pathway GO:0019221 9.02 SOS1 IL7 IL6 CXCL8 CSF2

Molecular functions related to Acute Monoblastic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL7 IL6 EPO CXCL8 CSF2

Sources for Acute Monoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....